Company

Bolt Biotherapeutics was founded in 2015 by Dr. Edgar G. Engleman of Stanford University to expand upon his pioneering work in cancer immunotherapeutics and myeloid biology. Bolt is based in the San Francisco Bay area.

Bolt’s highly qualified management team includes experienced leaders in immuno-oncology drug discovery, development and commercialization. Our goal is to leverage our myeloid biology expertise to discover, develop and commercialize transformative treatments to address key unmet medical needs for patients with cancer.

Management Team

Randall Schatzman, Ph.D.

Chief Executive Officer

Randall Schatzman, Ph.D., chief executive officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr.

Randall Schatzman, Ph.D.

Chief Executive Officer

Randall Schatzman, Ph.D., chief executive officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are now currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer reviewed scientific publications.

Edith A. Perez, M.D.

Chief Medical Officer

Edith A. Perez, M.D., chief medical officer, joined Bolt Biotherapeutics in 2020 and is an internationally recognized translational researcher and cancer specialist known

Edith A. Perez, M.D.

Chief Medical Officer

Edith A. Perez, M.D., chief medical officer, joined Bolt Biotherapeutics in 2020 and is an internationally recognized translational researcher and cancer specialist known for her strategic vision in designing innovative clinical trials and passion of the patient. She is Professor of Medicine at Mayo Clinic and Director of the Mayo Clinic Breast Cancer Translational Genomics Program, where she has practiced for two decades. Prior to joining Bolt, Dr. Perez was the vice president and head of the BioOncology-U.S. medical affairs unit at Genentech for three years. She earned her medical degree from the University of Puerto Rico School of Medicine in San Juan and completed her residency in internal medicine at the Loma Linda University Medical Center in California. In addition, she completed her fellowship training at the University of California, Davis. Dr. Perez is board certified in internal medicine, medical oncology and hematology.

William Quinn

Chief Financial Officer

Willie Quinn, chief financial officer, joined Bolt Biotherapeutics in 2020. Prior to joining Bolt, Willie served as the chief financial officer and senior vice president

William Quinn

Chief Financial Officer

Willie Quinn, chief financial officer, joined Bolt Biotherapeutics in 2020. Prior to joining Bolt, Willie served as the chief financial officer and senior vice president corporate development of Sunesis Pharmaceuticals (SNSS). He led Sunesis’ fundraising and partnering efforts, raising over $60 million in public funding and signing multiple deals with industry partners. Prior to Sunesis he led Bullet Biotechnology, a company that he co-founded to develop cancer immunotherapies based on technology from Stanford University, as chief executive officer. Willie was instrumental in establishing the infrastructure at Jazz Pharmaceuticals (JAZZ), where he was one of the first employees and worked for more than eight years. He rose to head of corporate development, also overseeing strategy and investor relations, helping Jazz transform from a private startup to a public, profitable specialty pharmaceutical company. Before Jazz, Willie was the chief financial officer and chief operating officer of Novation Biosciences, a biotechnology software company that was acquired by Agilent Technologies. He currently serves on the board of A Foundation Building Strength, a nonprofit with a mission to find treatments for Nemaline Myopathy. Willie earned an M.A. and B.A. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

Grant Yonehiro

Chief Business Officer

Grant Yonehiro joined Bolt Biotherapeutics as the company’s chief business officer in 2016. Grant has been responsible for business and corporate development, strategy,

Grant Yonehiro

Chief Business Officer

Grant Yonehiro joined Bolt Biotherapeutics as the company’s chief business officer in 2016. Grant has been responsible for business and corporate development, strategy, commercialization and general management within biotechnology companies for over 25 years with significant transactional and operational responsibilities. He served as president and chief executive officer of Perseid Therapeutics from inception through acquisition by Astellas Pharma and stayed on post-acquisition as president of an Astellas operating site. He served as chief business officer for Berkeley Lights and Maxygen and also held various senior management positions at GenVec including vice president of commercial operations, vice president of product management and vice president of drug development. Prior to GenVec, he served in business development at Cell Genesys, in investment banking at Piper Jaffray and in the Technology Transfer Office at Lawrence Berkeley National Laboratory. Grant graduated Magna Cum Laude from the University of Minnesota with a Bachelor of Individualized Studies and received his M.B.A. from the Haas School of Business at UC Berkeley.

David Dornan, Ph.D.

Senior Vice President, Research & Manufacturing

David Dornan, Ph.D., senior vice president of research & manufacturing, joined Bolt Biotherapeutics in 2017. He is working to harness the exciting technologies at Bol

David Dornan, Ph.D.

Senior Vice President, Research & Manufacturing

David Dornan, Ph.D., senior vice president of research & manufacturing, joined Bolt Biotherapeutics in 2017. He is working to harness the exciting technologies at Bolt to discover and develop therapeutics that may exploit myeloid cell biology to generate a robust anti-tumor immune response. Prior to Bolt, Dr. Dornan led Oncology Research at Gilead and was working to build a group dedicated to identifying and developing anti-cancer therapeutics that could have utility in PD1-refractory patients that encompassed immuno-oncology and cancer driver targeted therapies. Before that, he spent 10 years at Genentech serving in roles of increasing responsibility and played key roles in target discovery and validation, as well as translational research programs to determine the optimum patient population that would benefit from Genentech’s anti-cancer therapeutics across large and small molecule programs. He began his tenure at Genentech as a post-doctoral fellow where he pursued his interest in identifying potential novel druggable targets in the laboratory of Dr. Vishva Dixit. Dr. Dornan received his Ph.D. from the University of Dundee in the United Kingdom for studies on cancer-dependent gene transcription.

Michael N. Alonso, Ph.D.

Vice President, Immunology & Pharmacology

Michael Alonso, Ph.D., vice president of immunology & pharmacology, is a scientific co-founder at Bolt Biotherapeutics and co-invented Bolt’s promising technology.

Michael N. Alonso, Ph.D.

Vice President, Immunology & Pharmacology

Michael Alonso, Ph.D., vice president of immunology & pharmacology, is a scientific co-founder at Bolt Biotherapeutics and co-invented Bolt’s promising technology. Michael is passionate about translating scientific discoveries into therapies that ensure cancer patients become cancer survivors. Dr. Alonso has deep expertise with myeloid biology and has over 10 years of experience in immunology, neuroscience and transplant biology. Prior to joining Bolt, Michael served as the lead scientist at a Bay Area biotechnology start-up and has held leadership roles at Stanford University. Michael is a well-published scientist who earned his Ph.D. from Stanford University School of Medicine and his Certificate in Entrepreneurship from Stanford’s Graduate School of Business. Michael graduated with distinction from the University of Illinois at Urbana-Champaign where he obtained his bachelors of science in molecular and cellular biology.

Amreen Husain, M.D.

Vice President, Clinical Development & Translational Medicine

Amreen Husain, M.D., vice president of clinical development & translational medicine, joined Bolt Biotherapeutics in 2020 bringing 10 years of experience in oncology

Amreen Husain, M.D.

Vice President, Clinical Development & Translational Medicine

Amreen Husain, M.D., vice president of clinical development & translational medicine, joined Bolt Biotherapeutics in 2020 bringing 10 years of experience in oncology drug development with a focus on breast and gynecologic cancers, immuno-oncology, and drug safety. Prior to joining Bolt, Amreen was at Roche/Genentech in roles of increasing responsibility in late-stage Oncology Development leading cross-functional teams in the development of Atezolizumab and Bevacizumab. She is an internationally recognized leader in clinical research with over 50 peer-reviewed publications and has served on cooperative groups and international professional societies. She previously practiced at Stanford University Medical Center as Associate Professor of Gynecologic Oncology and is board-certified in Obstetrics and Gynecology and Gynecologic Oncology. Amreen obtained her MD from New York Medical College, completed her Ob/Gyn residency at Cornell University Medical Center, and her gynecologic oncology fellowship at Memorial-Sloan Kettering Cancer Center.

Nathan Ihle, Ph.D.

Vice President, CMC & Quality

Nathan Ihle, Ph.D., vice president of CMC & quality, joined Bolt Biotherapeutics in 2019. Prior to joining Bolt, he was the founder and Principal at Ihle CMC Solution

Nathan Ihle, Ph.D.

Vice President, CMC & Quality

Nathan Ihle, Ph.D., vice president of CMC & quality, joined Bolt Biotherapeutics in 2019. Prior to joining Bolt, he was the founder and Principal at Ihle CMC Solutions. He has also served as the vice president of manufacturing strategy at Immunomedics, where he developed and implemented the supply strategy and supported the global commercialization of the company’s first antibody-drug conjugate product. He was also a key contributor to the company’s regulatory submissions. Before working at Immunomedics, Dr. Ihle worked for 16 years at Seattle Genetics as the vice president of CMC strategy and management. At Seattle Genetics, Dr. Ihle was responsible for CMC aspects of development and regulatory strategies for all corporate programs, portfolio and project management and alliance management. Dr. Ihle completed his post-doctoral work as an American Cancer Society Postdoctoral fellow at University of California, Berkeley after receiving his doctorate in Organic Chemistry from Stanford University.

Marcin Kowanetz, Ph.D.

Vice President, Target Validation & Translational Sciences

Marcin Kowanetz, Ph.D., vice president of target validation & translational sciences, joined Bolt Biotherapeutics in 2018. He brings 13 years of pharmaceutical experi

Marcin Kowanetz, Ph.D.

Vice President, Target Validation & Translational Sciences

Marcin Kowanetz, Ph.D., vice president of target validation & translational sciences, joined Bolt Biotherapeutics in 2018. He brings 13 years of pharmaceutical experience in drug discovery and development, with focus on cancer immunotherapy for molecules in early and late clinical stage. Prior to Bolt, Dr Kowanetz served at Genentech in roles of increasing responsibility in Oncology Biomarker Development, including biomarker lead for atezolizumab (anti-PD-L1) and overseeing cross functional teams identifying, developing, and implementing biomarker strategies for therapies at various stages of clinical development. Prior to that, he was in Research Drug Discovery where he focused on the identification and characterization of novel targets for the treatment of cancer. He is passionate about understanding mechanisms of response and resistance to cancer immunotherapy and developing personalized immunotherapies. Dr. Kowanetz has over 35 published papers, is named on several patents and has contributed chapters to multiple medical research textbooks. He holds a Ph.D. from the Ludwig Institute for Cancer Research at Uppsala University in Sweden and a Master of Science degree from the Institute of Molecular Biology at Jagiellonian University in Krakow, Poland.

Triona O’Hanlon

Vice President, Project Management

Triona O'Hanlon joined Bolt Biotherapeutics in 2020 as the vice president of program management. She has over 20 years of drug development experience spanning biologics,

Triona O’Hanlon

Vice President, Project Management

Triona O'Hanlon joined Bolt Biotherapeutics in 2020 as the vice president of program management. She has over 20 years of drug development experience spanning biologics, small molecules and cellular therapeutics in oncology, inflammation and neurology. Prior to joining Bolt, Triona was at Gilead Sciences for seven years, where she led the program management group for Hematology/Oncology division and Kite, Gilead's cell therapy division.

Prior to joining Gilead, Triona held program and alliance management roles at Ambit Biosciences, overseeing early development of Quizartinib, a FLT3 inhibitor, as well as Elan Pharmaceuticals, where she supported the clinical development and launch of Tysabri in collaboration with Biogen and lead the early development of an oral anti α4β7 integrin in rheumatoid arthritis.

Triona holds a BSc in Biochemistry and Biochemical Engineering from Dublin City University.

Brian Safina, Ph.D.

Vice President, Medicinal Chemistry & Bioconjugation

Brian Safina, Ph.D., serves as vice president of medicinal chemistry & bioconjugation for Bolt Biotherapeutics. He joined Bolt in 2018 with over 14 years of experienc

Brian Safina, Ph.D.

Vice President, Medicinal Chemistry & Bioconjugation

Brian Safina, Ph.D., serves as vice president of medicinal chemistry & bioconjugation for Bolt Biotherapeutics. He joined Bolt in 2018 with over 14 years of experience in large pharma and has made contributions in multiple therapeutic areas including oncology, immunology and neuroscience. Prior to Bolt, Dr. Safina was at Genentech where he served in roles of increasing responsibility in Discovery Chemistry, which included serving as a project team leader for early and late stage projects with 30+ team members. He has published over 25 papers, and is named on over 25 granted patents and more than 10 patent applications. Dr. Safina holds a Ph.D. in organic chemistry from the University of California, San Diego.

Laurie Torres

Vice President, Human Resources

Laurie Torres, vice president of human resources, joined Bolt Biotherapeutics in 2020 with more than 20 years of HR experience at rapid-growth, innovative companies from

Laurie Torres

Vice President, Human Resources

Laurie Torres, vice president of human resources, joined Bolt Biotherapeutics in 2020 with more than 20 years of HR experience at rapid-growth, innovative companies from pre-IPO to Fortune 500. She specializes in partnering with executives and business leaders to develop and execute strategic solutions for breakout growth. Prior to Bolt, Laurie served as Sr. Vice President of Human Resources at BlackThorn Therapeutics where she developed a strategic roadmap to guide the company from the pre-IPO stage to a competitive public company. In addition, she previously held HR Leadership and operations positions at Veracyte, WCG, PDL BioPharma and Genentech. Laurie also founded XLHR Solutions, an HR firm that provides scalable strategic and tactical services to early-stage companies. She received her Bachelor of Science in Human Resources from California State University-East Bay.

Board of Directors

Edgar G. Engleman, M.D.

Founder and Director

Dr. Ed Engleman is professor of pathology and medicine at Stanford University Sc

Edgar G. Engleman, M.D.

Founder and Director

Dr. Ed Engleman is professor of pathology and medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. He is also co-director of the Immunology and Immunotherapy Program of the Stanford Cancer Institute. Dr. Engleman has authored more than 300 publications in medical and scientific journals and has trained more than 100 graduate students and postdoctoral scholars, many of whom have gone on to successful careers in industry and academia. Dr. Engleman is a co-founder and managing partner of Vivo Capital, a leading healthcare focused investment firm with offices in the U.S. and Asia. He has also co-founded a number of biopharmaceutical companies including Genelabs, Dendreon, Medeor and Tranquis. He is the lead inventor of the technology underlying Sipuleucel-T (Provenge), which was shown to extend life for patients with metastatic prostate cancer and was the first active immunotherapeutic agent to be approved by the FDA. Recently, Dr. Engleman’s laboratory discovered a promising new immunotherapy that activates dendritic cells in tumors in situ without requiring their removal and activation in vitro. This treatment was shown to eradicate a wide range of tumors in mouse models and provided the basis for the creation of Bolt Biotherapeutics. Dr. Engleman currently serves on the boards of several private biotechnology companies including Bolt. He received his B.A. from Harvard University and his M.D. from Columbia University School of Medicine.

Ashish Khanna, Ph.D.

Director

Dr. Ash Khanna is a Venture Partner at Pivotal bioVenture Partners and brings si

Ashish Khanna, Ph.D.

Director

Dr. Ash Khanna is a Venture Partner at Pivotal bioVenture Partners and brings significant experience in the venture capital, pharmaceutical and biotech arena. Most recently, he co-founded SutroVax, a Pivotal bioVenture Partners portfolio company, where he served as chief business officer. Previously he was president and chief business officer of Imagen Biotech, a VC-backed startup developing treatments for severe ophthalmic diseases. Prior to his operating roles, Dr. Khanna was a principal at SV Life Sciences (SVLS), a healthcare focused venture capital firm, where he led and managed investments in many biotech and diagnostic companies including, among others, Ophthotech, Sutro BioPharma, Mpex Pharmaceuticals, Good Start Genetics and Itero Biopharma. He started his career in the pharmaceutical industry at Bristol-Myers Squibb where he held various positions including Team Leader responsible for the clinical advancement of multiple diabetes programs including the currently marketed products, Onglyza® (Dipeptidyl peptidase-4 inhibitor) and Farxiga® (SGLT2 inhibitor). Dr. Khanna is a co-inventor on the Onglyza® patent. Dr. Khanna holds a Ph.D. in Pharmaceutics from the State University of New York, an M.B.A. in Finance from The Wharton School, and a B.S. in Pharmacy from the University of Bombay.

Richard A. Miller, M.D.

Director

Dr. Richard Miller currently serves as co-founder, president and chief executive

Richard A. Miller, M.D.

Director

Dr. Richard Miller currently serves as co-founder, president and chief executive officer of Corvus Pharmaceuticals, a public biotechnology company. He co-founded and was chief executive officer of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, vice president and director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School, summa cum laude and completed residency and fellowship programs in internal medicine and medical oncology at Stanford University Medical Center. He is a board-certified oncologist and is currently adjunct clinical professor of medicine (oncology) at Stanford University Medical Center.

Peter Moldt, Ph.D.

Chairman of the Board

Dr. Peter Moldt joined Novo Ventures (US) Inc. in San Francisco, California in 2

Peter Moldt, Ph.D.

Chairman of the Board

Dr. Peter Moldt joined Novo Ventures (US) Inc. in San Francisco, California in 2012. He is a member of the boards of directors of Bolt Biotherapeutics, Corvus Pharmaceuticals Inc., E-Scape Bio., Outpost and Viewpoint. Prior to that, Peter was employed with Novo A/S as a partner in Novo Ventures in Denmark. In 2004, Peter co-founded Curalogic A/S, a company he took public, where he served as chief executive officer for five years.  Before that, he was chief operating officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development. Peter holds a Ph.D. in medicinal chemistry from the Royal Danish School of Pharmacy. He has also been a post doc with Yale University's department of organic chemistry.

Jason Pitts, Ph.D.

Director

Dr. Jason Pitts joined Sofinnova Investments as an Associate in 2018 and was pro

Jason Pitts, Ph.D.

Director

Dr. Jason Pitts joined Sofinnova Investments as an Associate in 2018 and was promoted to Principal in 2019. At Sofinnova he led investments in Karuna Therapeutics and Athira Pharma. He also serves as a Board Observer for Velos Biopharma and Cincor Pharma.

Prior to joining Sofinnova, Jason was a consultant with McKinsey & Company, focusing primarily on operational and strategic R&D issues for top companies in pharmaceuticals and medical products. Before transitioning to consulting, Jason studied the genetic mechanisms of neurodegenerative disease as a graduate student at The Rockefeller University in the lab of Dr. Marc Tessier-Lavigne, founder of Denali Therapeutics and current Stanford University president. Prior to enrolling at Rockefeller, Jason worked as a research associate at Regeneron Pharmaceuticals, Inc.

Jason received his Ph.D. in Neuroscience from The Rockefeller University, where he was awarded The David Rockefeller Fellowship, and a BS in Neurobiology and Behavior from Cornell University.

Randall Schatzman, Ph.D.

CEO and Board Member

Dr. Randall Schatzman, chief executive officer and board member, joined Bolt Bio

Randall Schatzman, Ph.D.

CEO and Board Member

Dr. Randall Schatzman, chief executive officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are now currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer reviewed scientific publications.

Mahendra G. Shah, Ph.D.

Director

Dr. Mahendra G. Shah is a pharmaceutical entrepreneur and executive who has been

Mahendra G. Shah, Ph.D.

Director

Dr. Mahendra G. Shah is a pharmaceutical entrepreneur and executive who has been at healthcare investment firm, Vivo Capital, since March 2010. He is also the founder and executive chairman of Semnur Pharmaceuticals. Dr. Shah currently serves on the boards of Homology Medicines Inc. (NASDAQ: FIXX) and Soleno Therapeutics Inc (NASDAQ: SLNO), and is a member of the board of trustees of St. John’s University. Dr. Shah is also a board member and charter member of EPPIC and a charter member of TIE.

From 2005 to 2009, he was the founder, chairman and chief executive officer of NextWave Pharmaceuticals, a pediatric focused specialty pharmaceutical company, which was sold to Pfizer for a total of $700 million in upfront and milestone payments. From 1993 to 2003 he was the chairman and chief executive officer of First Horizon Pharmaceuticals, a publicly traded specialty pharmaceutical company, where he raised over $200 million and built a highly profitable company before it was sold to Shionogi Pharmaceuticals for $1.4 billion. Prior to that, he held positions with E. J. Financial Enterprises, which manages a fund that invests in healthcare companies and with Fujisawa USA (Astellas), and before that, he worked in various scientific and management positions with Schering-Plough and Bristol Myers-Squibb. He previously served on the boards of Unimed Pharmaceuticals (UMED), Introgen Therapeutics (INGN), Inpharmakon, Protomed, Structural Bioinformatics, and Zarix. Dr. Shah received his Ph.D. in industrial pharmacy from St. John’s University and his Bachelors and Masters Degrees in Pharmacy from L.M. College of Pharmacy in Gujarat, India.

Scientific Advisory Board

Lawrence Fong, M.D.

Cancer Immunotherapy Program Leader

Lawrence Fong, M.D., is an Efim Guzik distinguished professor in the Division of Hematology/Oncology at the Un

Lawrence Fong, M.D.

Cancer Immunotherapy Program Leader

Lawrence Fong, M.D., is an Efim Guzik distinguished professor in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF). Dr. Fong is focused on developing immunotherapies for different cancers including prostate, kidney, bladder, melanoma, and GI cancers. As a physician-scientist, Dr. Fong also leads a translational immunotherapy laboratory. He has been involved in both pre-clinical and clinical studies for many cutting-edge immunotherapies. Dr. Fong obtained his M.D. at Stanford University, completed internal medicine training at the University of Washington, and an oncology fellowship at Stanford University with Drs. Ed Engleman and Mark Davis focused on tumor immunology. He served on the program committees and editorial boards for ASCO and AACR. He is co-director of the Parker Institute for Cancer Immunotherapy at UCSF and is the site primary investigator for the NCI-sponsored Cancer Immunotherapy Trials Network (CITN).

Priti Hegde, Ph.D.

Chief Scientific Officer

As chief scientific officer at Foundation Medicine, Priti Hegde, Ph.D., oversees clinical product development,

Priti Hegde, Ph.D.

Chief Scientific Officer

As chief scientific officer at Foundation Medicine, Priti Hegde, Ph.D., oversees clinical product development, cancer genomics and early-stage research, as well as regulatory strategies for the company’s comprehensive genomic profiling portfolio. Prior to joining Foundation Medicine, Dr. Hegde spent 12 years at Genentech, a member of Roche Group, most recently serving as senior director and principal scientist in oncology biomarker development, during which she established and led the biomarker group accountable for translational science strategies in cancer immunotherapy. Dr. Hegde was instrumental in the approvals for atezolizumab in both the United States and European Union as well as its forthcoming diagnostic filings. Prior to Genentech, she worked at GlaxoSmithKline. Dr. Hegde completed her post-doctoral fellow at The Institute for Genomic Research and holds a Ph.D. in Biochemical Pharmacology from SUNY Buffalo, as well as a B. Pharmacy from Mumbai University, India.

Roy S. Herbst, M.D., Ph.D.

Chief of Medical Oncology, Director for Translational Research

Roy S. Herbst, M.D., Ph.D., is ensign professor of medicine, professor of pharmacology, chief of medical oncol

Roy S. Herbst, M.D., Ph.D.

Chief of Medical Oncology, Director for Translational Research

Roy S. Herbst, M.D., Ph.D., is ensign professor of medicine, professor of pharmacology, chief of medical oncology, director of the Thoracic Oncology Research Program, and associate director for translational research at Yale Cancer Center (YCC) and Yale School of Medicine. Dr. Herbst has worked over several decades as a pioneer of personalized medicine and immunotherapy, serving as principal investigator for numerous clinical trials for advanced stage lung cancers. This work led to the approval of several therapies (such as Gefitinib, Cetuximab, Bevacizumab, Axitinib, Atezolizumab, and Pembrolizumab), which have revolutionized the field and greatly enhanced patient survival. His work on "umbrella” trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. He works closely with public-private partnerships to develop large clinical studies, such as Lung-MAP. He is a member of the American Association of Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology (ASCO). Dr. Herbst’s work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.

Nils Lonberg, Ph.D.

Executive in Residence

Nils Lonberg is currently an Executive in Residence at Canaan Partners. Dr. Lonberg led drug discovery and pla

Nils Lonberg, Ph.D.

Executive in Residence

Nils Lonberg is currently an Executive in Residence at Canaan Partners. Dr. Lonberg led drug discovery and platform development teams in the biotech and pharma industry for the last 30 years, most recently as Senior Vice President, Oncology Discovery Biology, at Bristol-Myers Squibb. Prior to that he was Scientific Director at Genpharm International and Medarex, where his research groups developed genetically engineered strains of mice with human immunoglobulin genes that have been used to discover 10 FDA-approved antibody therapeutics, including ipilimumab and nivolumab, two drugs discovered by Dr. Lonberg’s team that target immune-attenuating pathways to activate patient immune responses to multiple cancers (so-called "checkpoint blockade" therapies). Dr. Lonberg received his PhD in Biochemistry and Molecular Biology from Harvard University (Cambridge, MA) in 1985, and was elected to the National Academy of Engineering in 2015.

Bruce D. Roth, Ph.D.

Principal

Bruce D. Roth, Ph.D. is best known as the inventor of Lipitor®, for which he has received numerous awards, in

Bruce D. Roth, Ph.D.

Principal

Bruce D. Roth, Ph.D. is best known as the inventor of Lipitor®, for which he has received numerous awards, including the 2013 Perkin Medal, the highest award given to industrial chemists in the United States. Dr. Roth is now active as a biopharmaceutical research consultant. Prior to founding his consulting practice, between the years of 2007 and 2017, he held positions of increasing responsibility at Genentech, the last one being senior vice president of gRED (Genentech Research and Early Development) small molecule drug discovery and co-leader of gRED research. Before that, he served as vice president of chemistry at Pfizer Global Research and Development, Ann Arbor Laboratories, and prior to that, was an adjunct associate professor in the Department of Medicinal Chemistry in the School of Pharmacy of the University of Michigan.